FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy
Related Topics >> Avandia | Diabetes | EMEA | Actos

Actos on a good-news roll

Tools

The EU's drug committee also gave the go-ahead for a new combo pill that melds the diabetes remedy Actos with old blood-sugar standby metformin. This thumbs-up follows a spate of good news for Actos, including a new study unveiled Wednesday that showed it controlled blood sugar and lipid levels better than Avandia did. Another study, presented at the same meeting of the European Association for the Study of Diabetes, showed that Actos cut heart attack risk by 38 percent.

- check out this EMEA release on the Actos combo drug
- and this release on the Actos studies

Related Articles:
Actos study points to reduction in heart attacks, strokes. Report
Diabetes drug helps reduce rate of strokes. Report
Avandia risks back in the headlines. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FiercePharma Email Newsletter:

More stories about Avandia   Diabetes   EMEA   Actos